Advances in Melanoma Treatment The incidence of melanoma has increased, but mortality
has declined with improved management. Sentinel-node sampling has reduced morbidity …

Importance Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma
(CM) is rising despite a lack of endorsement as standard of care. Objective To develop …

Aim Sentinel lymph node status is a central prognostic factor for melanomas. However, the
surgical excision involves some risks for affected patients. In this study, we therefore aimed …

PURPOSE National guidelines recommend sentinel lymph node biopsy (SLNB) be offered
to patients with> 10% likelihood of sentinel lymph node (SLN) positivity. On the other hand …

Background Many patients with low-stage cutaneous melanoma will experience tumor
recurrence, metastasis, or death, and many higher staged patients will not. Objective To …

Despite significant progress in the development of treatment options, melanoma remains a
leading cause of death due to skin cancer. Advances in our understanding of the genetic …

Purpose Patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for
adjuvant therapies despite uncertainty in relapse risk. Here, we studied the ability of a …

Multiple types of genomic variations are present in cutaneous melanoma and some of the
genomic features may have an impact on the prognosis of the disease. The access to …

Simple Summary The increase in adjuvant treatment of melanoma patients makes it
necessary to provide the most accurate prognostic assessment possible, even at early …

Lymph node metastasis (LNM) is often regarded as an indicator of poor prognosis in various
cancers. Despite over three centuries of exploration since its discovery, the molecular …